Excitement is building at Resonance Health regarding promising results from a prototype liver fibrosis measurement. The prototype has been demonstrated to distinguish between low and high fibrosis scores in a patient cohort with Hepatitis C.
Chief Scientific Officer Professor Tim St Pierre has submitted an abstract to the American Association for the Study of Liver Disease (AASLD) summarising the results. If accepted, the abstract will be published on 1st Oct 2015 and will be presented at the AASLD Liver Meeting to be held in San Francisco (November 13th-17th).
Liver fibrosis can be caused by a number of factors including chronic liver disease resulting from Hepatitis C, non-alcoholic fatty liver disease (NAFLD), high alcohol intake, or a compromised immune system. Liver fibrosis may ultimately lead to cancer of the liver.
A standardised, accurate test to non-invasively measure liver fibrosis would offer clinicians vital information on their patients’ liver condition. Such a test could be used either in isolation or in conjunction with Resonance Health’s HepaFat-Scan® to measure liver fat and FerriScan® to measure liver iron. Currently the most widely used method for measuring liver fibrosis is through liver biopsy which is invasive, painful and can be subject to inaccuracy. A non-invasive three-fold test of fibrosis, iron and fat would provide an overall summary of patients’ liver health; enabling clinicians to make better informed decisions regarding patient management.
Mr Sander Bangma, General Manager of Resonance Health said
“Reaching this stage of development for a fibrosis measurement is an exciting achievement and we are currently working to obtain new data to test the technology in a variety of clinical scenarios. We are also exploring other avenues to perform validation studies of the technology including partnership with pharma companies developing therapies to treat this increasingly prevalent condition.”
To read the ASX Announcement please click here